PD173074 is a potent and selective inhibitor of fibroblast growth factor receptors (FGFRs), particularly FGFR1. It is widely used in research to study signaling pathways involved in cell proliferation, differentiation, and survival. Due to its ability to block FGFR-mediated signaling, it has become a valuable tool in cancer research, especially in models where FGFR overexpression or mutation drives tumor growth, such as in certain breast, lung, and bladder cancers. It is also applied in studies of angiogenesis, as FGFR signaling plays a key role in blood vessel formation. By inhibiting this pathway, PD173074 helps researchers assess the dependency of tumors on angiogenic mechanisms. Additionally, it has been used in developmental biology to investigate the role of FGF signaling in embryogenesis and tissue repair. Because of its specificity, PD173074 is often used to validate the effects of FGFR-targeted therapies and to explore mechanisms of drug resistance in preclinical models. Its application remains primarily in vitro and in animal studies, supporting the development of new targeted cancer treatments.